SDC1 and prostate cancer: To overcome the challenges of delivery and catalysis that appear to have limited the toxicity of the sortilin 11H8-MMAE and syndecan-1 6D11-MMAE ADCs in prostate cancer cells, a radiolabelled ligand may be used to exploit the antibody targeting and offer an alternative approach for cancer cell killing.